22505_Managing Hyperkalemia in Heart Failure: Implementing Strategies to Reduce Patient Risk

In this symposium, attendees will be provided with best practices by a multidisciplinary faculty on the prevention of hyperkalemia, identification of patients at risk for hyperkalemia, the importance of maintaining HF patients on RAASis and preferably at target doses, recent clinical evidence with novel potassium binders, and strategies for effective communication with patients.

Hyperkalemia, characterized by elevated serum potassium levels, is prevalent in patients with heart failure (HF),
especially those taking renin-angiotensin-aldosterone system inhibitors (RAASis), therapies which decrease the risk of cardiovascular morbidity and mortality and are
recommended in HF guidelines. Despite strong evidence for cardiorenal protective effects of RAASis, hyperkalemia (or fear of hyperkalemia) is a major driver of underuse and
underdosing of RAASis in HF; these actions place HF patients at increased risk since dose reduction or discontinuation of RAASis is associated with worse outcomes in HF. Other
traditional therapeutic approaches to the treatment of chronic hyperkalemia, including dietary potassium restriction, use of diuretics, and administration of sodium
polystyrene sulfonate (SPS), also suffer from limitations like gastrointestinal side effects, variable effi cacy, and delayed onset of action. In recent years, the development of novel
potassium binders has revolutionized the management of hyperkalemia. These agents have demonstrated rapid and sustained reductions in serum potassium levels in multiple
clinical trials. Recent data have indicated that novel potassium binders not only effectively lower potassium levels but also reduce the risk of down-titration or
discontinuation of guideline-recommended, foundational therapies such as mineralocorticoid receptor antagonists (MRAs). In this symposium, attendees will be provided
with best practices by a multidisciplinary faculty on the prevention of hyperkalemia, identifi cation of patients at risk for hyperkalemia, the importance of maintaining HF patients
on RAASis and preferably at target doses, recent clinical evidence with novel potassium binders, and strategies for effective communication with patients.

Login to your Account